Mutation profile of ZNF7O3 gene in 23 samples.

A) Type of variants that occurred in the gene. B) Distribution of substitutions per sample. C) Distribution of substation type. D) The mutation viewed under IGV showing deletion of GCGCCCGCCGC and insertion of G in sample 237.

Mutation profile of ZNF75O gene in 23 patients.

A) Type of variants that occurred in the gene. B) Distribution of substitutions within the gene per sample, C) The frequency by which the substitutions occurred in the gene, D) The distribution of indels in the gene, E) The impact of mutation on ZNF75O gene.

Mutation profile of ZNF217 gene in 23 patients.

A) Type of variants that occurred in the gene, B) Distribution of substitutions within the gene per sample, C) The frequency by which the substitutions occurred in the gene, D) Variant classification of all the mutations, E) The type of mutations causes by C/T substitution, and F) The frameshift mutation of TA T substituted by a termination codon (Ter) as viewed under IGV.

The association between ZNF mutations and HER2 status.

A) The distribution of total ZNF217 mutations stratified by HER2 status; no significance difference (t= −0.022, df = 21. P= 0.9825), B) The distribution of ZNF7O3 mutations stratified by HER2 status; no statistical difference (t = −2.45, df = 21, p = 0.0229), C) The distribution of ZNF750 mutations stratified by HER2 status, no statistical difference (t= −0.587, df = 21, p= 0.5637).

The association between ZNF mutations and Cancer Stage.

A) The distribution of total ZNF217 mutations across cancer stages 1, 2, and 3; ANOVAtest, no significant differences between the groups (stage 2 vs. stage 1: p = 0.999; stage 3 vs. stage 1: p = 0.539; stage 3 vs. stage 2: p = 0.321), B) The distribution of ZNF7O3 mutations across cancer stages 1, 2, and 3; ANOVAtest, no statistically significant differences between any pair of cancer stages (stage 2 vs. stage 1: p = 0.456; stage 3 vs. stage 1: p = 0.358; stage 3 vs. stage 2: p = 0.946), C) The distribution of ZNF75O mutations across cancer stages 1, 2, and 3, ANOVA test, (stage 2 vs. stage 1: p = 0.507; stage 3 vs. stage 1: p = 0.351; stage 3 vs. stage 2: p = 0.896).

Principal Component Analysis (PCA) of ZNF217, ZNF7O3, and ZNF75O expression in 23 paired breast tissues.

Normal samples (gray) cluster tightly, while tumor samples show increasing dispersion across stages (Stage 1: blue, Stage 2: green, Stage 3: orange), reflecting greater variability with progression. The first two components explain 58.46% and 24.77% of the variance, driven by tumor-specific changes in expression.

DGE for ZNF75O, ZNF217, and ZNF7O3 genes.

The significant expression (p < 0.05) is normalized for each gene in both conditions, with normal samples represented in blue and tumor samples in red.

A) The distribution of RNA-Seq expression data for ZNF75O genes based on cancer stage. Each dot represents the difference in expression between normal and tumor sample, those above the gradient line represents ZNF75O genes highly expressed in tumor samples for the 23 patients; those below the line represents the gene highly expressed in normal sample. B) The box plot showing Log2 fold change (>2 or <l/2) of expression counts of ZNF75O gene per HER2 status and cancer stage of the 23 patients.

A) The distribution of RNA-Seq expression data for ZNF7O3 genes based on cancer stage. Each dot represents the difference in expression between normal and tumor sample, those above the gradient line represents ZNF75O genes highly expressed in tumor samples for the 23 patients. B) Log2 fold change (>2 or <1/2) of expression counts of ZNF7O3 gene per HER2 status and cancer stage of the 23 patients.

A) The distribution of RNA-Seq expression data for ZNF217 genes based on cancer stage. Each dot represents the difference in expression between normal and tumor sample, those above the gradient line represents ZNF75O genes highly expressed in tumor samples for the 23 patients. B) Log2 fold change (>2 or <l/2) of expression counts of ZNF217 gene per HER2 status and cancer stage of the 23 patients..

The correlation analysis between ZNF mutations and expression differences.

A) The correlation analysis between ZNF217 mutations and expression differences, B) The correlation analysis for the ZNF7O3 gene demonstrated notable associations, C) A correlation analysis between ZNF75O expression differences and mutation.